eoadjuvant Gemcitabine+nab-Paclitaxel for resectable and borderline resectable pancreatic cancer-feasibility study for the elderly
Phase 2
- Conditions
- Resectable and Borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000048555
- Lead Sponsor
- Hyogo Prefectural Awaji Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with active multiple cancer lesions 2) Patients with any history of serious allergic reaction 3) Patients with serious comorbidity (Infectious, respiratory, cardiac, kidney and liver diseases) 4) Patients who are judged as inappropriate research subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method